ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301

ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 ... Read More